Results 191 to 200 of about 312,196 (386)

Deep Vein Thrombosis in Critically Ill Patients with COVID‐19 Pneumonia

open access: yesJournal of Ultrasound in Medicine, EarlyView.
Objectives The risk of major venous thromboembolism (VTE) among patients with COVID‐19 is high but varies with disease severity. Estimate the incidence of lower extremity deep venous thrombosis (DVT) in critically ill hospitalized patients with COVID‐19, validate the Wells score for DVT diagnosis, and determine patients' prognosis.
Clévio Cezar da Fonseca   +20 more
wiley   +1 more source

Cutaneous Vasculitis as a Covid‐19 Manifestation: A Cross‐Sectional Study With Detailed Histopathological Evaluation

open access: yesJEADV Clinical Practice, EarlyView.
Multiple cutaneous manifestations have been linked with COVID‐19, including cutaneous vasculitis, ranging from mild or asymptomatic to fulminant. We conducted a comprehensive study investigating the cutaneous and histopathological manifestations of vasculitis in 33 patients with COVID‐19.
Reem Diab   +8 more
wiley   +1 more source

Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19

open access: yesThe Lancet Haematology, 2020
Taojiao Wang   +9 more
semanticscholar   +1 more source

Unravelling the Major Cardiovascular Risks of Systemic Psoriasis Medications: A Literature Systematic Review

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Psoriasis is a chronic inflammatory dermatological condition associated with an elevated risk of cardiovascular events (CVEs). Systemic therapies have transformed disease management, but their cardiovascular (CV) safety profiles remain incompletely understood and inconsistently reported.
Mai Thi Hoai Son   +10 more
wiley   +1 more source

Safety of Baricitinib for the Treatment of Atopic Dermatitis in Adults Over a Median of 1.6 and up to 4.6 Years Treatment: Final Integrated Analysis of Eight Clinical Trials

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Background Baricitinib is a selective Janus kinase (JAK)1/JAK2 inhibitor approved in more than 70 countries for the treatment of moderate‐to‐severe atopic dermatitis (AD) in adults, and in over 30 countries for adolescents and children from age 2 years with moderate‐to‐severe AD, who are candidates for systemic therapy.
Antonio Costanzo   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy